CagriSema
Also called cagrilintide + semaglutide
- Evidence
- Extensive research
- Class
- Amylin + GLP-1 combination
CagriSema belongs to the Amylin + GLP-1 combination class. This library groups it under digestive & weight. Its source category is In clinical trials.
At a glance
| Compound class | Amylin + GLP-1 combination |
|---|---|
| Body system | Digestive & weight |
| Use or research focus | Obesity; type 2 diabetes |
| Regulatory status | Investigational (Phase 3) |
| Source evidence rating | Extensive research |
How does CagriSema work?
Dual amylin/GLP-1 agonism.
The source catalog maps this mechanism to Pancreas, Brain / CNS, Whole-body / Metabolic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog places this compound in its strongest research tier below approved-drug evidence. Study quality, population, outcomes, and follow-up still matter. A research rating alone does not establish that a treatment is appropriate for an individual.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is CagriSema?
CagriSema belongs to the Amylin + GLP-1 combination class. This library groups it under digestive & weight. Its source category is In clinical trials. Its recorded use or research focus is: Obesity; type 2 diabetes.
Is CagriSema FDA-approved?
The catalog records: Investigational (Phase 3). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog places this compound in its strongest research tier below approved-drug evidence. Study quality, population, outcomes, and follow-up still matter. A research rating alone does not establish that a treatment is appropriate for an individual.
Where can I read the research?
The Citations tab contains 14 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for digestive & weight
Factual catalog fields and citation links are adapted from Superpower’s CagriSema guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with CagriSema in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01GLP-1 receptorncbi.nlm.nih.gov
- 02amylindoi.org
- 03submitted it to the FDAsec.gov
- 04REDEFINE 1doi.org
- 05REDEFINE 2doi.org
- 06cannot be used in compounding under federal lawfda.gov
- 0720.9% at 72 weekspubmed.ncbi.nlm.nih.gov
- 08did not meet its goal of showing non-inferioritysec.gov
- 0922.7% figure assumed all participants stayed on treatmentsec.gov
- 10mean body weight change was -20.4%pubmed.ncbi.nlm.nih.gov
- 1172.5%pubmed.ncbi.nlm.nih.gov
- 12label warns of acute gallbladder diseasedailymed.nlm.nih.gov
- 13showed no clinically relevant QTc prolongationpubmed.ncbi.nlm.nih.gov
- 14range from about 15% or lesspubmed.ncbi.nlm.nih.gov